9969 — InnoCare Pharma Balance Sheet
0.000.00%
Last trade - 00:00
- HK$12.16bn
- HK$5.71bn
- CNY738.54m
- 11
- 12
- 87
- 25
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 2,375 | 3,996 | 6,287 | 9,054 | 8,285 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15.8 | 52 | 66.2 | 145 | 319 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,409 | 4,089 | 6,417 | 9,300 | 8,765 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 99.9 | 330 | 546 | 696 | 834 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 2,642 | 4,541 | 7,415 | 10,329 | 9,920 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 65 | 97.3 | 317 | 2,068 | 2,082 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 5,647 | 1,437 | 1,810 | 2,732 | 2,772 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -3,005 | 3,104 | 5,605 | 7,597 | 7,148 |
Total Liabilities & Shareholders' Equity | 2,642 | 4,541 | 7,415 | 10,329 | 9,920 |
Total Common Shares Outstanding |